This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Helixate NexGen, Kogenate SF, Kogenate Bayer, Antihemophilic Factor Recombinant, Formulated with Sucrose, BAY14-2222
Description: Kogenate is manufactured using recombinant DNA technology in a way that includes a purification and formulation process that eliminates the addition of albumin and incorporates sucrose as a stabilizer in the final formulation. Kogenate provides a means of temporarily replacing the missing clotting factor FVIII in order to correct or prevent bleeding episodes, allowing the body’s blood-clotting process to function properly. (Kogenate FS succeeded Kogenate (R), which was was approved in 1993 and contained human albumin as a stabilizer.)
Kogenate FS News
Pink Sheet Bayer Kogenate FS recall
Additional information available to subscribers only: